Publications by authors named "F J Carapeto"
Introduction: The incidence of melanoma has been increasing in recent decades. BRAF mutations appear in 50%-70% of melanomas. The BRAF-targeted therapy increased the disease-free survival of patients with metastatic melanoma, but this response may be short, due to several resistance mechanisms, such as the presence of other subclones with mutations.
View Article and Find Full Text PDFArticle Synopsis
- A phase 1/1b study is being conducted to evaluate the safety and recommended dose of intrathecal (IT) nivolumab, given alongside intravenous (IV) nivolumab, for treating patients with melanoma and leptomeningeal disease (LMD).
- The study, which involved 25 metastatic melanoma patients, found no dose-limiting toxicities, establishing the safe IT nivolumab dose at 50 mg administered with 240 mg of IV nivolumab every two weeks.
- The median overall survival (OS) was 4.9 months, with 44% of patients alive at 26 weeks and 26% at 52 weeks, indicating potential effectiveness while
Multiplatform Analysis of Intratumoral PTEN Heterogeneity in Melanoma.
J Invest Dermatol
September 2023
Loss of protein expression of the tumor suppressor PTEN is associated with increased cancer aggressiveness, decreased tumor immune infiltration, and resistance to immune and targeted therapies in melanoma. We assessed a unique cohort of eight melanoma samples with focal loss of PTEN protein expression to understand the features and mechanisms of PTEN loss in this disease. We compared the PTEN-negative (PTEN[-]) areas to their adjacent PTEN-positive (PTEN[+]) areas using DNA sequencing, DNA methylation, RNA expression, digital spatial profiling, and immunohistochemical platforms.
View Article and Find Full Text PDFArticle Synopsis
- Undifferentiated pleomorphic sarcoma (UPS) shows significant immune infiltration, with immune checkpoint inhibitors benefiting around 20% of patients, leading to an investigation of the tumor's immune microenvironment and its impact on patient outcomes.
- Researchers performed immunohistochemistry on 105 surgically removed UPS samples, assessing various immune markers and correlations related to overall and disease-free survival using statistical methods.
- Key findings revealed that certain immune markers (like CD39 and CD73) were linked to treatment responsiveness and survival rates, with significant variations seen in primary vs. recurrent and metastatic tumors, highlighting the complexity of immune interactions in UPS.